open access

Vol 5, Supp. A (2009)
suplement
Published online: 2009-04-29
Get Citation

The approach to antiangiogenic therapy in cancer patients

Marek Z. Wojtukiewicz, Ewa Sierko

open access

Vol 5, Supp. A (2009)
suplement
Published online: 2009-04-29

Abstract

New vessel formation facilitates local tumor progression and distant metastases formation. Angiogenesis is a very complex process, which demands well-coordinated activity of various factors during consecutive steps. The balance between pro- and antiangiogenic factors shifted towards the former ones is a prerequisite for the initiation of angiogenesis. VEGF is the most important factor contributing to the new vessel formation. Its biological activity depends on the presence and activity of different receptors, eg. VEGFR-2, VEGFR-1, neuropilin 1, Tie2 receptor system, ephrin system, etc.
In experimental models blocking VEGF activity results in diminished interstitial pressure and improved cytotoxic drugs tissue penetration. In clinical settings, interfering with VEGF activity allowed for improved treatment outcomes in cancer patients. However, despite promising results, many questions remain opened, eg. the optimal selection of cancer patients for such a treatment, the way of therapy monitoring as well as the length of antiangiogenic treatment.

Abstract

New vessel formation facilitates local tumor progression and distant metastases formation. Angiogenesis is a very complex process, which demands well-coordinated activity of various factors during consecutive steps. The balance between pro- and antiangiogenic factors shifted towards the former ones is a prerequisite for the initiation of angiogenesis. VEGF is the most important factor contributing to the new vessel formation. Its biological activity depends on the presence and activity of different receptors, eg. VEGFR-2, VEGFR-1, neuropilin 1, Tie2 receptor system, ephrin system, etc.
In experimental models blocking VEGF activity results in diminished interstitial pressure and improved cytotoxic drugs tissue penetration. In clinical settings, interfering with VEGF activity allowed for improved treatment outcomes in cancer patients. However, despite promising results, many questions remain opened, eg. the optimal selection of cancer patients for such a treatment, the way of therapy monitoring as well as the length of antiangiogenic treatment.
Get Citation

Keywords

angiogenesis; cancer; VEGF; VEGF receptor; hypoxia; antiangiogenic agents

About this article
Title

The approach to antiangiogenic therapy in cancer patients

Journal

Oncology in Clinical Practice

Issue

Vol 5, Supp. A (2009)

Pages

1-14

Published online

2009-04-29

Keywords

angiogenesis
cancer
VEGF
VEGF receptor
hypoxia
antiangiogenic agents

Authors

Marek Z. Wojtukiewicz
Ewa Sierko

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl